JP2024513972A - Rnaサイレンシング剤および使用方法 - Google Patents

Rnaサイレンシング剤および使用方法 Download PDF

Info

Publication number
JP2024513972A
JP2024513972A JP2023562698A JP2023562698A JP2024513972A JP 2024513972 A JP2024513972 A JP 2024513972A JP 2023562698 A JP2023562698 A JP 2023562698A JP 2023562698 A JP2023562698 A JP 2023562698A JP 2024513972 A JP2024513972 A JP 2024513972A
Authority
JP
Japan
Prior art keywords
nucleic acid
nucleotide
acid according
antisense strand
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513972A5 (cg-RX-API-DMAC7.html
Inventor
ジェン リー,
ジーチン ジョウ,
Original Assignee
エーダーエックス ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーダーエックス ファーマシューティカルズ, インコーポレイテッド filed Critical エーダーエックス ファーマシューティカルズ, インコーポレイテッド
Publication of JP2024513972A publication Critical patent/JP2024513972A/ja
Publication of JP2024513972A5 publication Critical patent/JP2024513972A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/331—Universal or degenerate base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2023562698A 2021-04-13 2022-04-13 Rnaサイレンシング剤および使用方法 Pending JP2024513972A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163174507P 2021-04-13 2021-04-13
US63/174,507 2021-04-13
PCT/US2022/024692 WO2022221457A1 (en) 2021-04-13 2022-04-13 Rna silencing agents and methods of use

Publications (2)

Publication Number Publication Date
JP2024513972A true JP2024513972A (ja) 2024-03-27
JP2024513972A5 JP2024513972A5 (cg-RX-API-DMAC7.html) 2025-04-09

Family

ID=83639690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562698A Pending JP2024513972A (ja) 2021-04-13 2022-04-13 Rnaサイレンシング剤および使用方法

Country Status (7)

Country Link
US (1) US20240191229A1 (cg-RX-API-DMAC7.html)
EP (1) EP4323376A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024513972A (cg-RX-API-DMAC7.html)
CN (1) CN117425664A (cg-RX-API-DMAC7.html)
AU (1) AU2022257002A1 (cg-RX-API-DMAC7.html)
CA (1) CA3216732A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022221457A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
US20240401045A1 (en) 2021-10-01 2024-12-05 Adarx Pharmaceuticals, Inc. Angiotensinogen-modulating compositions and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012512651A (ja) * 2008-12-18 2012-06-07 ダイセルナ ファーマシューティカルズ, インコーポレイテッド 遺伝子発現の特異的阻害のための拡張dicer基質薬剤および方法
JP2013535982A (ja) * 2010-08-24 2013-09-19 メルク・シャープ・エンド・ドーム・コーポレイション 内部非核酸スペーサーを含む一本鎖RNAi剤関連出願の相互参照本出願は、2010年8月24日に出願された米国特許仮出願第61/376,471号の恩典を主張し、該仮出願は引用により本明細書に組み込まれる。
WO2016011123A1 (en) * 2014-07-16 2016-01-21 Arrowhead Research Corporation Organic compositions to treat apoc3-related diseases
JP2017537618A (ja) * 2014-12-17 2017-12-21 プロキューアール・セラピューティクス・セカンド・ベスローテン・フェンノートシャップProQR Therapeutics II B.V. 標的化rna編集

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
EP2264169A1 (en) * 2009-06-15 2010-12-22 Qiagen GmbH Modified siNA
KR101696704B1 (ko) * 2013-12-17 2017-01-16 주식회사 인코드젠 오프-타겟을 막기 위해 변형된 rna 간섭 유도 핵산 및 그 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012512651A (ja) * 2008-12-18 2012-06-07 ダイセルナ ファーマシューティカルズ, インコーポレイテッド 遺伝子発現の特異的阻害のための拡張dicer基質薬剤および方法
JP2013535982A (ja) * 2010-08-24 2013-09-19 メルク・シャープ・エンド・ドーム・コーポレイション 内部非核酸スペーサーを含む一本鎖RNAi剤関連出願の相互参照本出願は、2010年8月24日に出願された米国特許仮出願第61/376,471号の恩典を主張し、該仮出願は引用により本明細書に組み込まれる。
WO2016011123A1 (en) * 2014-07-16 2016-01-21 Arrowhead Research Corporation Organic compositions to treat apoc3-related diseases
JP2017537618A (ja) * 2014-12-17 2017-12-21 プロキューアール・セラピューティクス・セカンド・ベスローテン・フェンノートシャップProQR Therapeutics II B.V. 標的化rna編集

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUANG HUANG ET AL, NUCLEIC ACIDS RESEARCH, vol. 37, no. 22, JPN7026001114, 2009, pages 7560 - 7569, ISSN: 0005818139 *
NA WEI ET AL, PLOS ONE, vol. Vol. 7, Issue 11, Article number e49309, JPN7026001115, 2012, ISSN: 0005818140 *
QUAN DU ET AL, NUCLEIC ACIDS RESEARCH, vol. 33, no. 5, JPN7026001113, 2005, pages 1671 - 1677, ISSN: 0005818138 *
TOBY PASSIOURA ET AL, BMC BIOTECHNOLOGY, vol. Vol. 9, Article number 57, JPN7026001116, 2009, ISSN: 0005818141 *

Also Published As

Publication number Publication date
CA3216732A1 (en) 2022-10-20
EP4323376A4 (en) 2025-07-09
AU2022257002A1 (en) 2023-10-26
WO2022221457A1 (en) 2022-10-20
US20240191229A1 (en) 2024-06-13
EP4323376A1 (en) 2024-02-21
CN117425664A (zh) 2024-01-19

Similar Documents

Publication Publication Date Title
CN102575254B (zh) 利用不对称双链rna特异性抑制kras的方法和组合物
JP6295232B2 (ja) 修飾を有するdsRNAによる遺伝子発現の特異的な阻害のための組成物および方法
JP2022078069A (ja) 二本鎖RNAによるα-1アンチトリプシンの特異的阻害のための方法及び組成物
JP5816556B2 (ja) 治療剤のためのunaオリゴマー構造
CN100543137C (zh) 其它新形式的干扰rna分子
AU2011276365B2 (en) Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNA
JP2010525813A (ja) 二本鎖rnaによる遺伝子発現の特異的阻害のための、方法及び組成物
WO2004015075A2 (en) Short interfering rnas having a hairpin structure containing a non-nucleotide loop
CN101849008A (zh) 用于减少RNAi中的脱靶表型效应的siRNA的不依赖于序列的修饰形式和其稳定形式
JP2010503382A5 (cg-RX-API-DMAC7.html)
CN105907756A (zh) 延长的dicer酶底物和特异性抑制基因表达的方法
WO2010042636A2 (en) Telomerase inhibitors and methods of use thereof
CN112055598B (zh) 用于抑制gys2表达的组合物和方法
US20240191229A1 (en) Rna silencing agents and methods of use
JP4705370B2 (ja) より新規形態の干渉rna分子
US20220298507A1 (en) Compositions and methods for rna interference
Ma et al. Isonucleotide incorporation into middle and terminal siRNA duplexes exhibits high gene silencing efficacy and nuclease resistance
US20060019298A1 (en) Sequencing of modified nucleic acid molecules
Herold et al. Oligonucleotides as Recognition and Catalytic Elements
Yahyaee Anzahaee Structural studies and gene silencing activities of chemically modified nucleic acids: Effect of C2'sugar modifications and iso-nucleobases on the stability and polarity of duplex and tetraplex structures
Anzahaee Structural Studies and Gene Silencing Activities of Chemically Modified Nucleic Acids: Effect of C2'Sugar Modifications and Iso-nucleobases on the Stability and Polarity of Duplex and Tetraplex Structures
HK1148311A (en) Sirna sequence-independent modification formats for reducing off-target phenotypic effects in rnai, and stabilized forms thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260611